Anzu Special Acquisition I said its Feb. 9 shareholder meeting was adjourned until Feb. 21 when investors will consider an extension proposal that would push the SPAc’s deadline from March 4 to Sept. 30.
Anzu I earlier this week said it has signed a non-binding letter of intent to pursue a potential merger with Envoy Medical, which has developed an FDA-approved cochlear implant to aid individuals with severe hearing loss. The SPAC expects to execute a definitive agreement by the end of this month. Terms would include a requirement that Anzu have at least $40 million in trust at closing. Read more.
